Analyst Reiterates Rating on Ariad Pharm Today

Wall St. Watchdog reveals information about companies for which stock analysts reiterated their ratings on December 27th.

Ariad Pharm (NASDAQ:ARIA): Rodman & Renshaw reiterated its rating of Mkt Perform for this company and changed its price target from $15 to $18. About the company: ARIAD Pharmaceuticals, Inc. discovers, develops, and commercializes small-molecule drugs to treat aggressive cancers. The Company’s first product candidate is an investigational mTOR inhibitor. ARIAD’s second product candidate is an investigational pan BCR-ABL inhibitor for treatment of blood cancers. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

To contact the reporter on this story: Dave Friedman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com